Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device
- PMID: 2495893
- DOI: 10.1016/s0010-7824(89)80008-3
Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device
Abstract
Levonorgestrel, estradiol and progesterone plasma concentrations were measured over four years of use of a 20 micrograms/day levonorgestrel-releasing intracervical device (LNG-ICD). The mean levonorgestrel concentration showed a slight decline, being 142 + 46 (SD) pg/ml in the third month and 81 +/- 22 pg/ml in the 48th month of LNG-ICD use. However, considerable interindividual variation in levonorgestrel plasma levels between study subjects was observed. In 77% of the monitored cycles, ovulation or a luteinized follicle was observed when judged by a plasma progesterone elevation of over 5 ng/ml. Some follicular function was also noted in anovulatory cycles. Inhibition of ovulatory ovarian function is not the mode of contraceptive action of the LNG-ICD.
PIP: Levonorgestrel, estradiol and progesterone plasma concentrations were measured over 4 years of use of a 20 mcg/day levonorgestrel-releasing intracervical device (LNG-ICD). The mean levonorgestrel concentration showed a slight decline, being 142 +or- 46 (SD) pg/ml in the 3rd month and 81 +or- 22 pg/ml in the 48th month of LNG-ICD use. However, considerable inter-individual variation in levonorgestrel plasma levels between study subjects was observed. In 77% of the monitored cycles, ovulation or a luteinized follicle was observed when judged by a plasma progesterone elevation over 5 ng/ml. Some follicular function was also noted in anovulatory cycles. Inhibition of ovulatory ovarian function is not the mode of contraceptive action of the LNG-ICD.
Similar articles
-
Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.Contraception. 1995 Jun;51(6):359-65. doi: 10.1016/0010-7824(95)00102-g. Contraception. 1995. PMID: 7554977 Clinical Trial.
-
The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.Contraception. 1986 Nov;34(5):513-22. doi: 10.1016/0010-7824(86)90060-0. Contraception. 1986. PMID: 3102162
-
Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.Fertil Steril. 1997 Jul;68(1):59-64. doi: 10.1016/s0015-0282(97)81476-8. Fertil Steril. 1997. PMID: 9207585 Clinical Trial.
-
A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.Drug Saf. 1996 Dec;15(6):430-40. doi: 10.2165/00002018-199615060-00006. Drug Saf. 1996. PMID: 8968696 Review.
-
Does levonorgestrel emergency contraceptive have a post-fertilization effect? A review of its mechanism of action.Linacre Q. 2016 Feb;83(1):35-51. doi: 10.1179/2050854915Y.0000000011. Linacre Q. 2016. PMID: 27833181 Free PMC article. Review.
Cited by
-
Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling.Int J Womens Health. 2016 Oct 13;8:589-598. doi: 10.2147/IJWH.S99705. eCollection 2016. Int J Womens Health. 2016. PMID: 27785107 Free PMC article. Review.
-
Systematic Review of Postfertilization Effects and Potential for Embryo Formation and Loss during the Use of Intrauterine Devices.Linacre Q. 2020 Feb;87(1):60-77. doi: 10.1177/0024363919854289. Epub 2019 Jun 27. Linacre Q. 2020. PMID: 32431449 Free PMC article.
-
Drug release testing of long-acting intrauterine systems.J Control Release. 2019 Dec 28;316:349-358. doi: 10.1016/j.jconrel.2019.11.015. Epub 2019 Nov 13. J Control Release. 2019. PMID: 31733294 Free PMC article.
-
Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.Drug Saf. 2004;27(15):1185-204. doi: 10.2165/00002018-200427150-00003. Drug Saf. 2004. PMID: 15588115
-
Risk of intracranial hypertension with intrauterine levonorgestrel.Ther Adv Drug Saf. 2015 Jun;6(3):110-3. doi: 10.1177/2042098615588084. Ther Adv Drug Saf. 2015. PMID: 26240745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources